Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma Resubmission
(Notification to Implement Issued as of March 22, 2019)

Nivolumab (Opdivo) for Melanoma Adjuvant Therapy
(Notification to Implement Issued as of March 22, 2019)

Olaparib (Lynparza) for Newly Diagnosed Ovarian Cancer
(Pending Submission as of March 21, 2019)

Neratinib (Nerlynx) for Hormone Receptor-Positive Breast Cancer
(Pending Submission as of March 20, 2019)

Rituximab (Brand Name: TBD) for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar
(Pending Submission as of March 20, 2019)

Pomalidomide (Pomalyst) in combo with Dexamethasone and Bortezomib for Multiple Myeloma (second-line or beyond)
(Open for Input on Submission until March 29, 2019)

Bevacizumab (Brand Name: TBD) for Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer Biosimilar
(Open for Input on Submission until March 28, 2019)

Enasidenib (Idhifa) for Acute Myeloid Leukemia
(Pending Submission as of March 8, 2019)

Larotrectinib (Brand Name: TBD) for Neurotrophic Tyrosine Receptor Kinase Locally Advanced or Metastatic Solid Tumours
(Open for Input on Submission until March 11, 2019)

 

Find a Drug Review